Medical information Clinical review pending

Genetic Testing

NPM1 Gene Mutation Quantitative MRD Monitor Test

Monitor minimal residual disease (MRD) in leukemia patients with NPM1 mutations using the NPM1 Gene Mutation Quantitative MRD Monitor Test. Helps assess treatment response and relapse risk.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: 5 mL (3 mL minimum) whole blood or bone marrow collected in a Lavender Top (EDTA) tube.
Results: Confirm with the laboratory before booking.
Preparation: No specific patient preparation is required. Ensure the sample is collected in the correct tube type. Confirm with the laboratory before booking.

Test priceKSh 11,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the NPM1 Gene Mutation Quantitative MRD Monitor Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Monitoring treatment response in leukemia patients with NPM1 mutations.
✓Assessing risk of relapse after leukemia treatment.
✓Guiding further treatment decisions in NPM1-mutated leukemia.
✓Evaluating MRD levels in patients undergoing leukemia therapy.

In plain language

What this test helps you understand

This test helps monitor the effectiveness of leukemia treatment by quantifying the level of NPM1 gene mutations. It aids in assessing the risk of disease relapse and guides decisions regarding further therapy or monitoring frequency.

The NPM1 Gene Mutation Quantitative MRD Monitor Test is a specialized genetic test used to track minimal residual disease (MRD) in individuals diagnosed with leukemia, particularly those carrying mutations in the NPM1 gene. This test is crucial for monitoring how well treatment is working and identifying potential signs of disease recurrence early. It provides valuable information for oncologists and hematologists to guide patient care and make informed decisions about ongoing therapy. Understanding the level of NPM1 mutations helps assess the effectiveness of treatment and the risk of the leukemia returning. This test is recommended for patients with known NPM1 mutations in their leukemia.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required. Ensure the sample is collected in the correct tube type. Confirm with the laboratory before booking.

Sample5 mL (3 mL minimum) whole blood or bone marrow collected in a Lavender Top (EDTA) tube.

MethodologyQuantitative Polymerase Chain Reaction (qPCR) or similar molecular techniques to detect and quantify NPM1 gene mutations.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test specifically detects NPM1 gene mutations. Results are dependent on the quality of the sample provided. Interpretation requires clinical correlation. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

MRD stands for Minimal Residual Disease. It refers to the small number of cancer cells that may remain in the body after treatment, even when tests show no signs of cancer. Monitoring MRD helps predict the risk of relapse.

Mutations in the NPM1 gene are common in certain types of acute myeloid leukemia (AML). Monitoring these specific mutations helps track the disease activity and response to treatment.

The sample is typically collected as a blood draw or bone marrow aspiration. A healthcare professional will collect the required volume of blood or bone marrow in a specific tube.

The sample must be shipped refrigerated and should not be frozen. Please follow the specific instructions provided by the laboratory.

A positive result indicates the presence of NPM1 mutations above a certain threshold, while a negative result suggests they are below the detection limit. Your doctor will interpret these results in the context of your overall health and treatment.

Turnaround time varies. Please contact the laboratory for specific information regarding the expected timeframe for receiving your results.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp